144 related articles for article (PubMed ID: 25628399)
1. An Open-Label, Multicenter, Phase I/II Study of JNJ-40346527, a CSF-1R Inhibitor, in Patients with Relapsed or Refractory Hodgkin Lymphoma.
von Tresckow B; Morschhauser F; Ribrag V; Topp MS; Chien C; Seetharam S; Aquino R; Kotoulek S; de Boer CJ; Engert A
Clin Cancer Res; 2015 Apr; 21(8):1843-50. PubMed ID: 25628399
[TBL] [Abstract][Full Text] [Related]
2. Umbralisib, a novel PI3Kδ and casein kinase-1ε inhibitor, in relapsed or refractory chronic lymphocytic leukaemia and lymphoma: an open-label, phase 1, dose-escalation, first-in-human study.
Burris HA; Flinn IW; Patel MR; Fenske TS; Deng C; Brander DM; Gutierrez M; Essell JH; Kuhn JG; Miskin HP; Sportelli P; Weiss MS; Vakkalanka S; Savona MR; O'Connor OA
Lancet Oncol; 2018 Apr; 19(4):486-496. PubMed ID: 29475723
[TBL] [Abstract][Full Text] [Related]
3. The CSF-1-receptor inhibitor, JNJ-40346527 (PRV-6527), reduced inflammatory macrophage recruitment to the intestinal mucosa and suppressed murine T cell mediated colitis.
Manthey CL; Moore BA; Chen Y; Loza MJ; Yao X; Liu H; Belkowski SM; Raymond-Parks H; Dunford PJ; Leon F; Towne JE; Plevy SE
PLoS One; 2019; 14(11):e0223918. PubMed ID: 31710624
[TBL] [Abstract][Full Text] [Related]
4. Phase I Study of the Novel Investigational NEDD8-Activating Enzyme Inhibitor Pevonedistat (MLN4924) in Patients with Relapsed/Refractory Multiple Myeloma or Lymphoma.
Shah JJ; Jakubowiak AJ; O'Connor OA; Orlowski RZ; Harvey RD; Smith MR; Lebovic D; Diefenbach C; Kelly K; Hua Z; Berger AJ; Mulligan G; Faessel HM; Tirrell S; Dezube BJ; Lonial S
Clin Cancer Res; 2016 Jan; 22(1):34-43. PubMed ID: 26561559
[TBL] [Abstract][Full Text] [Related]
5. Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study.
Gadgeel SM; Gandhi L; Riely GJ; Chiappori AA; West HL; Azada MC; Morcos PN; Lee RM; Garcia L; Yu L; Boisserie F; Di Laurenzio L; Golding S; Sato J; Yokoyama S; Tanaka T; Ou SH
Lancet Oncol; 2014 Sep; 15(10):1119-28. PubMed ID: 25153538
[TBL] [Abstract][Full Text] [Related]
6. ENGAGE- 501: phase II study of entinostat (SNDX-275) in relapsed and refractory Hodgkin lymphoma.
Batlevi CL; Kasamon Y; Bociek RG; Lee P; Gore L; Copeland A; Sorensen R; Ordentlich P; Cruickshank S; Kunkel L; Buglio D; Hernandez-Ilizaliturri F; Younes A
Haematologica; 2016 Aug; 101(8):968-75. PubMed ID: 27151994
[TBL] [Abstract][Full Text] [Related]
7. LY3022855, an anti-colony stimulating factor-1 receptor (CSF-1R) monoclonal antibody, in patients with advanced solid tumors refractory to standard therapy: phase 1 dose-escalation trial.
Dowlati A; Harvey RD; Carvajal RD; Hamid O; Klempner SJ; Kauh JSW; Peterson DA; Yu D; Chapman SC; Szpurka AM; Carlsen M; Quinlan T; Wesolowski R
Invest New Drugs; 2021 Aug; 39(4):1057-1071. PubMed ID: 33624233
[TBL] [Abstract][Full Text] [Related]
8. JNJ-28312141, a novel orally active colony-stimulating factor-1 receptor/FMS-related receptor tyrosine kinase-3 receptor tyrosine kinase inhibitor with potential utility in solid tumors, bone metastases, and acute myeloid leukemia.
Manthey CL; Johnson DL; Illig CR; Tuman RW; Zhou Z; Baker JF; Chaikin MA; Donatelli RR; Franks CF; Zeng L; Crysler C; Chen Y; Yurkow EJ; Boczon L; Meegalla SK; Wilson KJ; Wall MJ; Chen J; Ballentine SK; Ott H; Baumann C; Lawrence D; Tomczuk BE; Molloy CJ
Mol Cancer Ther; 2009 Nov; 8(11):3151-61. PubMed ID: 19887542
[TBL] [Abstract][Full Text] [Related]
9. Safety, pharmacokinetic, and pharmacodynamics of erdafitinib, a pan-fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitor, in patients with advanced or refractory solid tumors.
Nishina T; Takahashi S; Iwasawa R; Noguchi H; Aoki M; Doi T
Invest New Drugs; 2018 Jun; 36(3):424-434. PubMed ID: 28965185
[TBL] [Abstract][Full Text] [Related]
10. A phase I dose-finding study of the novel Toll-like receptor 8 agonist VTX-2337 in adult subjects with advanced solid tumors or lymphoma.
Northfelt DW; Ramanathan RK; Cohen PA; Von Hoff DD; Weiss GJ; Dietsch GN; Manjarrez KL; Randall TD; Hershberg RM
Clin Cancer Res; 2014 Jul; 20(14):3683-91. PubMed ID: 24807889
[TBL] [Abstract][Full Text] [Related]
11. Phase 1 study of PTK787/ZK 222584, a small molecule tyrosine kinase receptor inhibitor, for the treatment of acute myeloid leukemia and myelodysplastic syndrome.
Roboz GJ; Giles FJ; List AF; Cortes JE; Carlin R; Kowalski M; Bilic S; Masson E; Rosamilia M; Schuster MW; Laurent D; Feldman EJ
Leukemia; 2006 Jun; 20(6):952-7. PubMed ID: 16617323
[TBL] [Abstract][Full Text] [Related]
12. A First-in-Human Phase 1 Study of LY3023414, an Oral PI3K/mTOR Dual Inhibitor, in Patients with Advanced Cancer.
Bendell JC; Varghese AM; Hyman DM; Bauer TM; Pant S; Callies S; Lin J; Martinez R; Wickremsinhe E; Fink A; Wacheck V; Moore KN
Clin Cancer Res; 2018 Jul; 24(14):3253-3262. PubMed ID: 29636360
[No Abstract] [Full Text] [Related]
13. Phase I dose escalation study of telatinib, a tyrosine kinase inhibitor of vascular endothelial growth factor receptor 2 and 3, platelet-derived growth factor receptor beta, and c-Kit, in patients with advanced or metastatic solid tumors.
Eskens FA; Steeghs N; Verweij J; Bloem JL; Christensen O; van Doorn L; Ouwerkerk J; de Jonge MJ; Nortier JW; Kraetzschmar J; Rajagopalan P; Gelderblom H
J Clin Oncol; 2009 Sep; 27(25):4169-76. PubMed ID: 19636022
[TBL] [Abstract][Full Text] [Related]
14. TAK-228 (formerly MLN0128), an investigational oral dual TORC1/2 inhibitor: A phase I dose escalation study in patients with relapsed or refractory multiple myeloma, non-Hodgkin lymphoma, or Waldenström's macroglobulinemia.
Ghobrial IM; Siegel DS; Vij R; Berdeja JG; Richardson PG; Neuwirth R; Patel CG; Zohren F; Wolf JL
Am J Hematol; 2016 Jun; 91(4):400-5. PubMed ID: 26800393
[TBL] [Abstract][Full Text] [Related]
15. A Single-Arm, Multicenter, Phase II Study of Camrelizumab in Relapsed or Refractory Classical Hodgkin Lymphoma.
Song Y; Wu J; Chen X; Lin T; Cao J; Liu Y; Zhao Y; Jin J; Huang H; Hu J; Luo J; Zhang L; Xue H; Zhang Q; Wang W; Chen C; Feng J; Zhu J
Clin Cancer Res; 2019 Dec; 25(24):7363-7369. PubMed ID: 31420358
[TBL] [Abstract][Full Text] [Related]
16. Phase II trial of denileukin diftitox for relapsed/refractory T-cell non-Hodgkin lymphoma.
Dang NH; Pro B; Hagemeister FB; Samaniego F; Jones D; Samuels BI; Rodriguez MA; Goy A; Romaguera JE; McLaughlin P; Tong AT; Turturro F; Walker PL; Fayad L
Br J Haematol; 2007 Feb; 136(3):439-47. PubMed ID: 17233846
[TBL] [Abstract][Full Text] [Related]
17. Phase 2 study of dovitinib in patients with relapsed or refractory multiple myeloma with or without t(4;14) translocation.
Scheid C; Reece D; Beksac M; Spencer A; Callander N; Sonneveld P; Kalimi G; Cai C; Shi M; Scott JW; Stewart AK
Eur J Haematol; 2015 Oct; 95(4):316-24. PubMed ID: 25402977
[TBL] [Abstract][Full Text] [Related]
18. First study of the safety, tolerability, and pharmacokinetics of CP-724,714 in patients with advanced malignant solid HER2-expressing tumors.
Munster PN; Britten CD; Mita M; Gelmon K; Minton SE; Moulder S; Slamon DJ; Guo F; Letrent SP; Denis L; Tolcher AW
Clin Cancer Res; 2007 Feb; 13(4):1238-45. PubMed ID: 17317835
[TBL] [Abstract][Full Text] [Related]
19. Phase II study of sorafenib in patients with relapsed or refractory lymphoma.
Guidetti A; Carlo-Stella C; Locatelli SL; Malorni W; Pierdominici M; Barbati C; Mortarini R; Devizzi L; Matteucci P; Marchianò A; Lanocita R; Farina L; Dodero A; Tarella C; Di Nicola M; Corradini P; Anichini A; Gianni AM
Br J Haematol; 2012 Jul; 158(1):108-19. PubMed ID: 22571717
[TBL] [Abstract][Full Text] [Related]
20. Panobinostat in patients with relapsed/refractory Hodgkin's lymphoma after autologous stem-cell transplantation: results of a phase II study.
Younes A; Sureda A; Ben-Yehuda D; Zinzani PL; Ong TC; Prince HM; Harrison SJ; Kirschbaum M; Johnston P; Gallagher J; Le Corre C; Shen A; Engert A
J Clin Oncol; 2012 Jun; 30(18):2197-203. PubMed ID: 22547596
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]